検索タンパク質、抗体、アッセイキット
タンパク質カタログ
輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。
- サプライヤー
- TargteMol
- カタログNo.
- TMPY-03674
- 製品名称
- RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc)
- タンパク質名
- RANKL/TNFSF11/CD254
- Species
- Human
- HOST
- HEK293 Cells
- 100μg: -
- お問い合わせ
Overview
| Synonyms | sOdf, tumor necrosis factor (ligand) superfamily, member 11, TNFSF11, TRANCE, ODF, CD254, OPTB2, hRANKL2, RANKL, OPGL |
|---|---|
| Characteristics | 1.Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF11B His at 2 μg/ml (100 μl/well) can bind Human RANKL mFc, the EC50 of Human RANKL mFc is 15-80 ng/mL. 2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 15-45 ng/mL. |
| Endotoxin Level | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Purity | 97.50% |
| Description | RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 52.4 kDa and the accession number is AAC51762.1. |
| Reference | Takayanagi H,et al.(2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32.,Nakashima T,et al.(2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7.,Leibbrandt A,et al.(2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.,Schwarz EM,et al.(2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7. |
| URL | https://www.targetmol.com/recombinant-protein/rankl_protein_human_recombinant_mfc_tag_ |
お問い合わせリスト